InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,732.81
(
0.25%
)
US TECH 100
19,412.40
(
0.47%
)
Dow Jones
42,174.26
(
0.12%
)
Brent Oil
74.42
(
0.92%
)
Bitcoin
63,249.53
(
-0.13%
)
Post# of 253207
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120487
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Wednesday, 08/20/2014 9:26:43 AM

Wednesday, August 20, 2014 9:26:43 AM

Post# of 253207
BMY, CELG ink clinical collaboration to test Opdivo (nivolumab) with Abraxane in multiple tumor types:

http://finance.yahoo.com/news/bristol-myers-squibb-celgene-enter-120000246.html

Financial terms were not disclosed, but it’s reasonable to infer that no cash is changing hands.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up